The State of Patient Access 2026
The access environment in 2026 is defined by the convergence of policy volatility, affordability concerns, restrictive payer management and systemic price sensitivity. To see how manufacturers are responding, MMIT and The Dedham Group conducted our third annual State of Patient Access survey of 285 pharma and biotech industry leaders. In this report, authors Hannah Baxter and Andrew Rouff share key findings and discuss the implications for the future of patient access.
Download the Report
The IRA is now functioning as a commercial filter, shaping which assets advance: 74% of manufacturers are adjusting their product investments to limit Medicare exposure.
Price sensitivity is now more systemic and externally driven, leaving 68% of manufacturers very concerned about their ability to sustain patient access to high-cost specialty drugs.
Most pharma execs (65%) say AI and RWD are very important or mission-critical to their patient access model today, with most use cases shifting to predictive strategies.